Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. more
Time Frame | VSTM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.24% | -2.06% | -0.55% |
1-Month Return | 11.52% | -1.92% | 2.72% |
3-Month Return | 57.2% | -10.4% | 7.66% |
6-Month Return | 30.28% | -4.6% | 10.15% |
1-Year Return | -45.45% | 4.06% | 27.53% |
3-Year Return | -84.43% | 1.94% | 32.31% |
5-Year Return | -70.42% | 36.48% | 89.2% |
10-Year Return | -95.89% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 17.46M | 88.52M | 2.05M | 2.60M | - | [{"date":"2019-12-31","value":19.72,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.32,"profit":true},{"date":"2022-12-31","value":2.93,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 2.81M | 33.74M | 206.00K | 118.00K | 62.00K | [{"date":"2019-12-31","value":8.32,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.61,"profit":true},{"date":"2022-12-31","value":0.35,"profit":true},{"date":"2023-12-31","value":0.18,"profit":true}] |
Gross Profit | 14.65M | 54.77M | 1.85M | 2.48M | (62.00K) | [{"date":"2019-12-31","value":26.75,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.37,"profit":true},{"date":"2022-12-31","value":4.52,"profit":true},{"date":"2023-12-31","value":-0.11,"profit":false}] |
Gross Margin | 83.92% | 61.88% | 89.97% | 95.45% | - | [{"date":"2019-12-31","value":87.92,"profit":true},{"date":"2020-12-31","value":64.82,"profit":true},{"date":"2021-12-31","value":94.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 146.99M | 104.13M | 63.46M | 75.53M | 92.08M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.84,"profit":true},{"date":"2021-12-31","value":43.17,"profit":true},{"date":"2022-12-31","value":51.39,"profit":true},{"date":"2023-12-31","value":62.65,"profit":true}] |
Operating Income | (132.34M) | (49.36M) | (61.41M) | (72.94M) | (92.08M) | [{"date":"2019-12-31","value":-13234100000,"profit":false},{"date":"2020-12-31","value":-4936000000,"profit":false},{"date":"2021-12-31","value":-6140900000,"profit":false},{"date":"2022-12-31","value":-7293700000,"profit":false},{"date":"2023-12-31","value":-9208400000,"profit":false}] |
Total Non-Operating Income/Expense | (33.09M) | (33.45M) | (19.58M) | (1.80M) | 6.09M | [{"date":"2019-12-31","value":-543.61,"profit":false},{"date":"2020-12-31","value":-549.46,"profit":false},{"date":"2021-12-31","value":-321.65,"profit":false},{"date":"2022-12-31","value":-29.52,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (149.21M) | (67.53M) | (71.20M) | (73.81M) | (87.37M) | [{"date":"2019-12-31","value":-14920900000,"profit":false},{"date":"2020-12-31","value":-6753200000,"profit":false},{"date":"2021-12-31","value":-7120000000,"profit":false},{"date":"2022-12-31","value":-7381200000,"profit":false},{"date":"2023-12-31","value":-8736700000,"profit":false}] |
Income Taxes | 19.97M | 194.00K | 9.90M | 36.00K | (87.37M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.97,"profit":true},{"date":"2021-12-31","value":49.58,"profit":true},{"date":"2022-12-31","value":0.18,"profit":true},{"date":"2023-12-31","value":-437.56,"profit":false}] |
Income After Taxes | (169.18M) | (67.73M) | (81.10M) | (73.85M) | - | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (149.21M) | (67.73M) | (71.20M) | (73.81M) | (76.81M) | [{"date":"2019-12-31","value":-14920900000,"profit":false},{"date":"2020-12-31","value":-6772600000,"profit":false},{"date":"2021-12-31","value":-7120000000,"profit":false},{"date":"2022-12-31","value":-7381200000,"profit":false},{"date":"2023-12-31","value":-7680700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (169.18M) | (67.73M) | (81.10M) | (73.85M) | (87.37M) | [{"date":"2019-12-31","value":-16917600000,"profit":false},{"date":"2020-12-31","value":-6772600000,"profit":false},{"date":"2021-12-31","value":-8110000000,"profit":false},{"date":"2022-12-31","value":-7384800000,"profit":false},{"date":"2023-12-31","value":-8736700000,"profit":false}] |
EPS (Diluted) | (2.01) | (0.39) | (0.41) | (0.38) | (3.22) | [{"date":"2019-12-31","value":-201,"profit":false},{"date":"2020-12-31","value":-39,"profit":false},{"date":"2021-12-31","value":-41,"profit":false},{"date":"2022-12-31","value":-38,"profit":false},{"date":"2023-12-31","value":-322,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VSTM | |
---|---|
Cash Ratio | 3.03 |
Current Ratio | 3.23 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VSTM | |
---|---|
ROA (LTM) | -47.31% |
ROE (LTM) | -136.87% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VSTM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.75 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.09 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VSTM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 20.47 |
P/B | 18.83 |
Price/FCF | NM |
EV/R | 15.77 |
EV/Ebitda | NM |
PEG | NM |
Verastem Inc (VSTM) share price today is $4.26
Yes, Indians can buy shares of Verastem Inc (VSTM) on Vested. To buy Verastem Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VSTM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Verastem Inc (VSTM) via the Vested app. You can start investing in Verastem Inc (VSTM) with a minimum investment of $1.
You can invest in shares of Verastem Inc (VSTM) via Vested in three simple steps:
The 52-week high price of Verastem Inc (VSTM) is $14.22. The 52-week low price of Verastem Inc (VSTM) is $2.1.
The price-to-earnings (P/E) ratio of Verastem Inc (VSTM) is
The price-to-book (P/B) ratio of Verastem Inc (VSTM) is 18.83
The dividend yield of Verastem Inc (VSTM) is 0.00%
The market capitalization of Verastem Inc (VSTM) is $204.73M
The stock symbol (or ticker) of Verastem Inc is VSTM